Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339275 | 1.00 | CCR5 (0.60) | CCR5CHRM2RIPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2337830 | 0.99 | CCR5 (0.59) | CCR5CHRM2RIPK1KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2337831 | 0.99 | CCR5 (0.59) | CCR5CHRM2RIPK1KDM4EALDH1A1 | |
| SCHEMBL2339380 | 0.93 | CCR5 (0.50) | CCR5RIPK1 | |
| SCHEMBL14371065 | 0.93 | CCR5 (0.50) | CCR5RIPK1 | |
| SCHEMBL2338626 | 0.93 | CCR5 (0.56) | CCR5RIPK1 | |
| SCHEMBL14371024 | 0.93 | CCR5 (0.56) | CCR5RIPK1 | |
| Hydrochloric Acid SCHEMBL2343459 | 0.92 | CCR5 (0.49) | CCR5RIPK1 | |
| Hydrochloric Acid SCHEMBL2334551 | 0.92 | CCR5 (0.55) | CCR5RIPK1 | |
| SCHEMBL2340099 | 0.90 | CCR5 (0.57) | CCR5CHRM2RIPK1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786815-B1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC (CA) | 2011-08-24 | — | — | EP | claimed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | claimed |
| US-20050070563-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIRO CHEM PHARMA, INC. (CA) | 2005-03-31 | — | — | US | claimed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288548-B2 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070563-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CCR5, CXCR2 | CCR5 2/4885CHRM2 472/4885RIPK1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.